Gliotoxin

Gliotoxin

SCHEMBL14986985

CN1C(=O)C23CC4=CC=CC(O)C4N2C(=O)C1(CO)SS3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 11/20 1.00
SUV39H1 O43463 3/20 1.00
PKM P14618 1/20 1.00
FNTA P49354 1/20 1.00
FNTB P49356 1/20 1.00
PGGT1B P53609 1/20 1.00
RNF31 Q96EP0 1/20 1.00
RBCK1 Q9BYM8 1/20 1.00
SHARPIN Q9H0F6 1/20 1.00
EP300 Q09472 6/20 0.45
HIF1A Q16665 5/20 0.45
NSD2 O96028 2/20 0.45
TXNRD1 Q16881 1/20 0.45
NSD1 Q96L73 1/20 0.45
NSD3 Q9BZ95 1/20 0.45
CREBBP Q92793 2/20 0.40
HKDC1 Q2TB90 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gliotoxin SCHEMBL4294337 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL9667270 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL12149513 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL14514067 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL13341245 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL12018743 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL12618354 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL14579856 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL54420 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB
Gliotoxin SCHEMBL20199940 1.00 EHMT2 (1.00) EHMT2SUV39H1PKMFNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
US-10450327-B2 Epidithiodioxopiperazine compound or its derivatives, and the use thereof VASTHERA CO. LTD. (KR) 2019-10-22 US disclosed
US-20190298732-A1 PHARMACEUTICAL COMPOSITION COMPRISING EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR PREVENTING OR TREATING PULMONARY HYPERTENSION VASTHERA CO. LTD (KR) 2019-10-03 US disclosed
US-9765090-B2 Epidithiodioxopiperazine compound or its derivatives, and the use thereof EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2017-09-19 US disclosed
US-9765090-B2 Epidithiodioxopiperazine compound or its derivatives, and the use thereof EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2017-09-19 US disclosed
US-20170239261-A1 EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF VASTHERA CO. LTD. (KR) 2017-08-24 US disclosed
US-20170239261-A1 EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF VASTHERA CO. LTD. (KR) 2017-08-24 US disclosed
US-20160222031-A1 EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2016-08-04 US disclosed
US-20160222031-A1 EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) 2016-08-04 US disclosed
WO-2013077709-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESTENOSIS COMPRISING EPIDITHIODIOXOPIPERAZINE COMPOUNDS OR DERIVATIVES THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF 이화여자대학교 산학협력단 (KR) 2013-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239261-A1 EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF PRDX1, PRDX2, PRDX5 EHMT2 2773/4885SUV39H1 1731/4885PKM 2952/4885
US-20190298732-A1 PHARMACEUTICAL COMPOSITION COMPRISING EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR PREVENTING OR TREATING PULMONARY HYPERTENSION IL5, NPPA, REN EHMT2 962/4885SUV39H1 755/4885PKM 2743/4885
US-20160222031-A1 EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF PRDX1, PRDX2, PRDX5 EHMT2 2773/4885SUV39H1 1731/4885PKM 2952/4885
US-10450327-B2 Epidithiodioxopiperazine compound or its derivatives, and the use thereof PRDX1, PRDX2, PRDX5 EHMT2 2773/4885SUV39H1 1731/4885PKM 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.